ANI Pharmaceuticals, Inc. Announces the Launch of Kionex Suspension
May 20, 2024 at 04:20 pm IST
Share
ANI Pharmaceuticals, Inc. announced the launch of Kionex (Sodium Polystyrene Sulfonate Suspension USP) for Oral or Rectal use. Kionex Suspension is the only commercially available therapeutically equivalent to the reference listed drug (RLD) SPS® Suspension for Oral or Rectal use. U.S. annual sales for Sodium Polystyrene Sulfonate Oral /Rectal Suspension total approximately $30.3 million, based on March 2024 moving annual total (MAT) IQVIA data.
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.
ANI PHARMACEUTICALS, INC. 
